Sheida Naderi-Azad has an expertise in immunodermatology, with a deep interest in melanoma immunotherapeutics, primary immunodeficiency diseases such as atopic dermatitis, and autoimmune conditions such as psoriasis. She has developed this interest upon completing her Bachelor of Science in Microbial and Environmental Pathophysiology at the University of British Columbia, and further completing a summer studentship at the Melanoma Clinic, Massachusetts General Hospital. She has had numerous published articles and presentations on melanoma therapeutics, anti-inflammatory conditions and dermatologic comorbidities such as mood disorders.
Statement of the Problem: Advanced melanoma involves metastasis to distant sites and is associated with poor long-term survival (Fisher et al., 2012). Current treatment options for melanoma include interleukin 2, targeted therapy (BRAFi, MEKi) and immunotherapy (CTLA4 antibody, PD1/PDL1 antibody). While targeted therapeutics can successfully block oncogenic signaling with high clinical response, they result in high relapse rates due to acquired resistance. Furthermore, while immunotherapeutics can induce durable responses, they have lower response rates due to immune evasion and suppression of effector function in tumour microenvironment. The purpose of this study is discuss the potential for combining immunotherapy and targeted therapy with the goal of achieving high response rates with prolonged duration. Methodology & Theoretical Orientation: To obtain these results, various search terms such as immunotherapy and targeted therapy were utilized. Furthermore, the articles were selected based on recency of publication as well as depth of detail regarding the specific immunologic mechanisms by combination therapies exert their effects. Findings: The results show that potential mechanisms of combinatorial activity of immunotherapy and targeted therapy include increasing antigen presentation, as well as improved lymphocyte homing and function. Yet it is important to note that long-term consequences of combinatorial therapeutics are uncertain, and clinical trials of combinations have resulted in adverse effects such as hepatotoxicity and intestinal perforation. Conclusion & Significance: Altogether, these results indicate a potential combination for BRAF-targeted therapy and immunotherapy in achieving long-term durable responses.
Dr.Warkaa get Ph.D inOral histology in 2013. head of oral pathology department from2016-2017,member in IDA, editorial board member in 5 medical and dental journal.Has one published book and 14 researchs and editorials. review about 12 research in dentistry. responsible for oral pathology lab in Mustansiriyah university.
Background and objective: -The use of low level laser therapy (LLLT) has been increased now a day to accelerate healing of soft tissue injuries because of some biostimulatory effects. The goal of this study was to investigate the effect of 790-805nm diode laser on the inflammatory effect of mast cells during wound healing in rodents. Materials and Methods: -A cut wound (1.5cm) was done on the cheek of 40albino mice. 20 of them exposed to LLLT (360 J/cm 2) at 790-805 nm immediately post wounding procedure. The animals were scarified and the wound area was prepared and stained with toluidine blue. Results: - Mean mast cell count of 10.2 on the first day of control group while in laser group 8.4. The control and laser group showed a gradual inclination in the mean value to be return to increase at the day 14 of the experiment. There was a significant difference (P< 0.05) in the control group on the first day. While significant difference (P≤0.05) was in the day 7. Pearson correlation showed a significant correlation (P≤0.01) between the control group at the day 1 and the laser group on the day 7. While there was a significant correlation (P≤0.05) between the control group at the day 14 and laser group on the day 1. Conclusions:- LLLT may induce an anti-inflammatory effect on wound healing process by its inhibitory action on mast cells; while it may have a biostimulatory effect on the proliferation of mast cells in the proliferative phase of wound healing which indirectly affects fibrous tissue regeneration in the subcutaneous area.